Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
---|
11/23/2000 | WO2000070049A2 Extracellular signaling molecules |
11/23/2000 | WO2000070048A1 POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES ENCODING MURINE ORGANIC ANION TRANSPORTER 6 (mOATP6) AND SCREENING METHODS THEREOF |
11/23/2000 | WO2000070047A2 Full-length molecules expressed in human tissues |
11/23/2000 | WO2000070046A2 Secreted polypeptides and corresponding polynucleotides |
11/23/2000 | WO2000070045A1 Ox2 receptor homologs |
11/23/2000 | WO2000070044A2 Human brain t calcium channel alpha-subunit splice variants |
11/23/2000 | WO2000070043A1 Recombinant human mannan-binding lectin |
11/23/2000 | WO2000070042A1 143 human secreted proteins |
11/23/2000 | WO2000070037A2 Directed evolution of microorganisms |
11/23/2000 | WO2000070036A2 Genes expressed in hippocampus |
11/23/2000 | WO2000070035A1 Inhibitors for viral infection targeting integrase n-terminal region |
11/23/2000 | WO2000070024A2 Infectious retroviruses from a leukemic dog cell line with extensive homologies to murine leukemia viruses |
11/23/2000 | WO2000070022A2 Ex vivo expansion of mammalian hematopoietic stem cells |
11/23/2000 | WO2000069981A1 A color containing silica resistant to dye migration and method of making the same |
11/23/2000 | WO2000069913A1 EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS |
11/23/2000 | WO2000069912A1 Gene encoding a sodium channel beta-3 subunit protein |
11/23/2000 | WO2000069911A1 Long lasting insulinotropic peptides |
11/23/2000 | WO2000069910A1 Chemokine-like factors having cell chemokinesis function and proliferation-stimulating activity |
11/23/2000 | WO2000069909A1 Isolation and characterization of epidermal growth factor related protein |
11/23/2000 | WO2000069908A1 Interaction between the vhl tumour suppressor and hypoxia inducible factor, and assay methods relating thereto |
11/23/2000 | WO2000069907A1 Protein scaffold and its use to multimerise monomeric polypeptides |
11/23/2000 | WO2000069906A1 Lawsonia derived gene and related hemolysin polypeptides, peptides and proteins and their uses |
11/23/2000 | WO2000069905A1 LAWSONIA DERIVED GENE AND RELATED OmpH POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES |
11/23/2000 | WO2000069904A1 LAWSONIA DERIVED GENE AND RELATED FlgE POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES |
11/23/2000 | WO2000069903A1 LAWSONIA DERIVED GENE AND RELATED SodC POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES |
11/23/2000 | WO2000069902A1 Long lasting fusion peptide inhibitors or viral infection |
11/23/2000 | WO2000069901A2 Proteins with insulin-like activity useful in the treatment of diabetes |
11/23/2000 | WO2000069900A2 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
11/23/2000 | WO2000069898A2 Molecular interactions in allergy cells |
11/23/2000 | WO2000069897A2 Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes |
11/23/2000 | WO2000069896A2 Molecular interactions in haematopoietic cells |
11/23/2000 | WO2000069895A2 Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins |
11/23/2000 | WO2000069894A2 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals |
11/23/2000 | WO2000069891A2 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins |
11/23/2000 | WO2000069888A1 Self-assembling biomolecular structures |
11/23/2000 | WO2000069886A2 Oligomeric chaperone proteins |
11/23/2000 | WO2000069885A2 Secreted proteins and uses thereof |
11/23/2000 | WO2000069884A2 Compositions isolated from skin cells and methods for their use |
11/23/2000 | WO2000069883A1 Methods for increasing plant cell proliferation by functionally inhibiting a plant cyclin inhibitor gene |
11/23/2000 | WO2000069881A1 Estrogen response element binding proteins and nucleotides encoding therefor |
11/23/2000 | WO2000069880A1 Il-9/il-2 receptor-like molecules and uses thereof |
11/23/2000 | WO2000069879A2 Ca7 cg04 gene |
11/23/2000 | WO2000069457A1 Protein a based binding domains with desirable activities |
11/23/2000 | WO2000069456A2 Adjuvant combination formulations |
11/23/2000 | WO2000069450A1 Oncogene identification by transformation of rk3e cells and uses thereof |
11/23/2000 | WO2000069449A2 Conditioned cell culture medium compositions and methods of use |
11/23/2000 | WO2000069443A1 ysxC |
11/23/2000 | WO2000069391A2 CRYSTAL STRUCTURE OF RIBOSOMAL PROTEIN L11/GTPASE ACTIVATING REGION rRNA AND USES THEREOF |
11/23/2000 | WO2000069256A1 Transgenically produced antithrombin iii and mutants thereof |
11/23/2000 | WO2000046375A3 Methods for producing polypeptides in fungal cells |
11/23/2000 | WO2000046245A3 Human antibiotic proteins |
11/23/2000 | WO2000046242A3 19 KILODALTON PROTEIN OF $i(HELICOBACTER PYLORI) |
11/23/2000 | WO2000043410A3 Novel odorant receptors in drosophila |
11/23/2000 | WO2000040752A3 Cancer associated genes and their products |
11/23/2000 | WO2000040711A8 Polycystic kidney disease gene homologs required for male mating behavior in nematodes and assays based thereon |
11/23/2000 | WO2000040615A3 EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS |
11/23/2000 | WO2000039150A3 Secreted proteins and uses thereof |
11/23/2000 | WO2000038706A3 Methods for treating cancer and for mediating chemotaxis of dendritic cells |
11/23/2000 | WO2000037685A9 Method of identifying a psychotropic agent using differential gene expression |
11/23/2000 | WO2000037502A3 Vascular endothelial cell growth factor antagonists and uses thereof |
11/23/2000 | WO2000036910A9 Msh5 ablated mice and uses therefor |
11/23/2000 | WO2000036124A3 Plant cell cycle genes and uses thereof |
11/23/2000 | WO2000036092A3 METHOD FOR THE HIGH LEVEL EXPRESSION OF ACTIVE LYMPHOTOXIN-β RECEPTOR IMMUNOGLOBULIN CHIMERIC PROTEINS AND THEIR PURIFICATION |
11/23/2000 | WO2000032782A3 Plant transcription factors |
11/23/2000 | WO2000032221A3 Promotion or inhibition of angiogenesis and cardiovascularization |
11/23/2000 | WO2000031283A3 Regulatory sequences useful for gene expression in plant embryo tissue |
11/23/2000 | WO2000031262A3 Human neurotensin subtype 2 receptor |
11/23/2000 | WO2000031124A3 Peptides that modulate the interaction of b class ephrins and pdz domains |
11/23/2000 | WO2000028020A3 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor |
11/23/2000 | WO2000028013A3 Gene expression modulated by activation of microglia or macrophages |
11/23/2000 | WO2000028011A3 Fk506-based regulation of biological events |
11/23/2000 | WO2000027994A3 Chlamydia pneumoniae genome sequence |
11/23/2000 | WO2000027429A3 Vaccine against papillomatous digital dermatitis (pdd) |
11/23/2000 | WO2000026357A3 Transgenic and cloned mammals |
11/23/2000 | WO2000023053A3 Artificial antigen-specific cells and related methods |
11/23/2000 | WO2000022093A3 Novel interferon stimulated and repressed genes |
11/23/2000 | WO2000021983A3 Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell |
11/23/2000 | WO2000020450A3 Calcium channel alpha-2/delta gene |
11/23/2000 | WO2000017369A3 Alzheimer's disease secretase |
11/23/2000 | WO2000016746A3 Immunogenic liposome compositions |
11/23/2000 | WO2000015790A3 Leptin induced genes |
11/23/2000 | WO2000015666A3 Compositions and methods for the treatment of tumors |
11/23/2000 | WO2000012740A3 Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences |
11/23/2000 | WO2000009666A3 Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof |
11/23/2000 | WO2000008157A3 Human anion transporter genes atnov |
11/23/2000 | WO2000007545A3 Apoptosis proteins |
11/23/2000 | WO2000004863A3 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
11/23/2000 | WO2000002523A3 Vaccine against staphylococcus intoxication |
11/23/2000 | WO1999057536A3 Cyclin activation kinase (cak) from human pathogens, and uses related thereto |
11/23/2000 | WO1999004775A3 Method of treating dopaminergic and gaba-nergic disorders |
11/23/2000 | DE19929802A1 Product containing deodorized marine collagen, useful e.g. as hemostatic sponge or drug carrier, optionally crosslinked to improve mechanical properties |
11/23/2000 | DE19926879A1 Detecting, isolating or quantifying basophils, mast cells and their precursors for diagnosing e.g. leukemia, comprises using antibodies |
11/23/2000 | DE19923168A1 Neue Fluoreszenzfarbstoffe und ihre Verwendung als Fluoreszenzmarker New fluorescent dyes and their use as fluorescent markers |
11/23/2000 | DE19918446A1 Verwendung von Coxsackievirus B3 zur Verbesserung der Transfektion von Zellen Use of coxsackievirus B3 to improve the transfection of cells |
11/23/2000 | DE10002892A1 New immunodominant peptides from actin, useful for diagnosis and treatment of type I autoimmune hepatitis |
11/23/2000 | CA2767116A1 Adjuvant combination formulations |
11/23/2000 | CA2623458A1 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
11/23/2000 | CA2505617A1 Modified secretin and method of synthesizing thereof |
11/23/2000 | CA2501421A1 Long lasting exendin-4 |
11/23/2000 | CA2499211A1 Modified peptides yy and conjugates thereof |